Surgery decision guided by new tumor measurement technology
Part of Cancer clinical trials.
This trial tests a new way to measure tumors in patients with a type of liver cancer called intrahepatic cholangiocarcinoma that has not spread to other parts of the body. The goal is to see if this measurement method can better guide decisions about surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with intrahepatic cholangiocarcinoma (a type of liver cancer)
- Your liver cancer is locally advanced (cannot be completely removed with surgery) and has not spread to other organs
- You have at least one tumor that can be measured on scans
- You have an ECOG performance status score of 0 (able to carry out all normal activities without restriction)
- Your liver function is Child-Pugh class A (well-preserved liver function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.